UBS Group
HOWL icon

UBS Group’s Werewolf Therapeutics HOWL Stock Holding History

UBS Group’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.7K Buy
215,838
+148,981
+223% +$90.8K ﹤0.01% 7324
2026
Q1 		$55.7K Buy
66,857
+6,149
+10% +$4.21K ﹤0.01% 7300
2025
Q4 		$38.4K Buy
60,708
+47,932
+375% +$58.3K ﹤0.01% 7363
2025
Q3 		$25.2K Buy
12,776
+9,338
+272% +$12.8K ﹤0.01% 8014
2025
Q2 		$3.75K Sell
3,438
-14,250
-81% -$14.7K ﹤0.01% 9323
2025
Q1 		$17.2K Sell
17,688
-12,805
-42% -$16.8K ﹤0.01% 8328
2024
Q4 		$45.1K Buy
30,493
+15,014
+97% +$30.6K ﹤0.01% 7365
2024
Q3 		$32.8K Buy
15,479
+5,671
+58% +$12.9K ﹤0.01% 7082
2024
Q2 		$23.9K Buy
9,808
+9,771
+26,408% +$46.9K ﹤0.01% 7189
2024
Q1 		$240 Sell
37
-963
-96% -$5.61K ﹤0.01% 8696
2023
Q4 		$3.86K Hold
1,000
– – ﹤0.01% 7925
2023
Q3 		$2.14K Hold
1,000
– – ﹤0.01% 7757
2023
Q2 		$3.05K Hold
1,000
– – ﹤0.01% 7664
2023
Q1 		$2.6K Sell
1,000
-448
-31% -$1.33K ﹤0.01% 8481
2022
Q4 		$2.97K Sell
1,448
-1,002
-41% -$2.62K ﹤0.01% 9592
2022
Q3 		$11K Sell
2,450
-1,807
-42% -$9.81K ﹤0.01% 8296
2022
Q2 		$18K Buy
4,257
+2,154
+102% +$9.83K ﹤0.01% 7011
2022
Q1 		$9K Sell
2,103
-7,356
-78% -$51.5K ﹤0.01% 8547
2021
Q4 		$113K Buy
9,459
+7,820
+477% +$118K ﹤0.01% 6199
2021
Q3 		$28K Buy
1,639
+639
+64% +$10.9K ﹤0.01% 6820
2021
Q2 		$17K Buy
+1,000
New +$13.7K ﹤0.01% 7506

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group's HOWL Position: Q2 2026 in Review

UBS Group increased its Werewolf Therapeutics (HOWL) stake by 223% in Q2 2026, buying an estimated $90.8K and bringing the position to 215,838 shares worth $77.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7324.

UBS Group first reported a position in HOWL in Q2 2021 and has held it in 21 quarters since. The position peaked at $113K in Q4 2021. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • UBS Group held 215,838 shares of Werewolf Therapeutics worth $77.7K as of Q2 2026.
  • UBS Group bought 148,981 Werewolf Therapeutics shares in Q2 2026, an estimated $90.8K.
  • Werewolf Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7324 holding.
  • UBS Group first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • UBS Group's Werewolf Therapeutics position peaked at $113K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.